Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/autre/economic-evaluation-in-genomic-medicine/descriptif_3781169
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=3781169

0 article 

 Frais de port 0,01€*

Exclusivité web : à partir de 35 euros d’achat, frais de port à 1 centime pour les expéditions vers la France métropolitaine, la Suisse et l’UE avec Colissimo ou GLS

Economic Evaluation in Genomic Medicine

Langue : Anglais

Auteurs :

Couverture de l’ouvrage Economic Evaluation in Genomic Medicine

Economic Evaluation in Genomic Medicine introduces health economics and economic evaluation to genomic clinicians and researchers, while also introducing the topic to health economists.

Each chapter includes an executive summary, questions, and case studies, along with supplementary online materials, including process guides, maps, flow charts, diagrams, and economic evaluation spreadsheets to enhance the learning process.

The text can easily be used as course material for related graduate and undergraduate courses, providing a succinct overview of the existing, state-of-the-art application of economic evaluation to genomic healthcare and precision medicine.

1. Economic evaluation in healthcare: Evidence-based medicine and evidence-based health economics2. Genomic Medicine today: an introduction for health economists3. Economic evaluation and genomic medicine: What can they learn from each other?4. Introduction to the technical issues of economic evaluation5. Advanced methodological aspects in the economic evaluation 6. Economic evaluation in the genomic era: Some examples from the field7. Special requirements for economic evaluation and health technology assessment in genomic medicine 8. A new methodological approach for cost-effectiveness analysis in Genomic Medicine9. Conclusions and future perspectives
Bioscientists, geneticists, biotech industry professionals, undergraduate and graduate students in health economics and health sciences, namely medicine, pharmacy, genetics, clinicians and health managers, public health officers, health policy makers, governmental organizations, health care professionals, hospital managers, healthcare policy makers
Christina Mitropoulou is Managing Director and Principal Investigator at the Golden Helix Foundation (London, UK), a registered UK-Charity with Research and Educational activities in the field of Genomic and Personalized Medicine. Her research interests revolve around the health economic evaluation of genome-guided therapeutic interventions. Also, Christina Mitropoulou participates as Executive Committee member of the Ubiquitous Pharmacogenomics (U-PGx) project and coordinates the health economic evaluation of the PREPARE clinical study on pre-emptive Pharmacogenomics testing, involving approx. 8000 patients from 7 clinical sites and she is an active member of the Pharmacogenomics Access and Reimbursement Coalition.
Christina Mitropoulou has published several original articles on this topic in leading scientific journals and has edited two textbooks on economic evaluation in Genomic Medicine that are published by Elsevier/Academic Press.

George P. Patrinos is Professor of Pharmacogenomics and Pharmaceutical Biotechnology in the University of Patras (Greece), Department of Pharmacy, Head of Division of Pharmacology and Biosciences of the same Department and holds adjunct Full Professorships at Erasmus MC, Faculty of Medicine, Rotterdam (the Netherlands) and the United Arab Emirates University, College of Medicine, Department of Genetics and Genomics, Al-Ain (UAE). Also, since March 2018, he is Chair of the Global Genomic Medicine Collaborative (G2MC) and since May 2023 Chairman of the Scientific Advisory Board of the ASPIRE Abu Dhabi Precision Medicine Research Institute. He has ample regulatory experience, as he served for 12.5 years as Full Member and Greece’s National representative in the CHMP Pharmacogenomics Working Party of the European Medicines Agency (EMA) and he is still an active member of the European Medicines Agency participating in expert panels to provide scientific advice where neede

  • Interrelates economic evaluation and genomic medicine
  • Instructs healthcare professionals and bioscientists about economic evaluation in genomic medicine
  • Teaches health economists about application of economic evaluation in genomic medicine
  • Introduces health economics and economic evaluation to clinicians and researchers involved in genomics
  • Includes process guides, maps, flow charts and diagrams